

Cascadian Therapeutics Investor Relations Department 2601 4th Avenue, Suite 500 Seattle, WA 98121 United States

Visit IR website □ Sign-up for email alerts □ □

NASDAQ: CASC	
Last Trade:	3.59
Trade Time:	4:00 PM ET Aug 16, 2017
Change:	-0.10 🖣 (-2.710%)
Day Range	3.56 - 3.74
52-Week Range	3.18 - 10.98
Volume	214,991

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

We are committed to serving the best interests of our shareholders. If you require assistance or have questions regarding the key shareholder information and financial reports available here please contact us.

... (more)

Stock Performance



Press Releases [View all]

Aug 8, 2017

<u>Cascadian Therapeutics Reports Second</u> <u>Quarter 2017 Financial Results</u>

Aug 1, 2017

<u>Cascadian Therapeutics to Report Second</u> <u>Quarter 2017 Financial Results on August 8, 2017</u>

Jul 11, 2017

<u>Cascadian Therapeutics Announces Positive</u> Regulatory Update for Tucatinib in Europe

Jun 8, 2017

Cascadian Therapeutics' Lead Candidate,
Tucatinib, Receives Orphan Drug
Designation from FDA for Treatment of
Breast Cancer Patients with Brain
Metastases

May 31, 2017

<u>Cascadian Therapeutics to Present at</u> Jefferies 2017 Healthcare Conference

Financials [View all]

Second Quarter Financial Results

Mar 9, 2017

Annual Report (10-K)

Apr 26, 2017

Proxy Statement (DEF 14A)

Aug 8, 2017

Quarterly Report (10-Q)

May 9, 2017

Quarterly Report (10-Q)

Nov 7, 2016

Quarterly Report (10-Q)